Top 50 Bioprinting

The startup develops a high-resolution 3D printer specifically designed for bioprinting live cells using optimized biocompatible materials. This technology enables the production of sterile support structures for tissue regeneration, facilitating the creation of precise microcomponents essential for cell research.

3DBio specializes in regenerative medicine by developing bioprinting technologies that create tissue-engineered constructs for medical applications. The company addresses the need for effective solutions in tissue repair and replacement, enhancing patient outcomes in regenerative therapies.

This biotech company develops bioprinted tissue therapeutics to create functional human tissues for transplantation and regenerative medicine. By addressing the shortage of donor organs and the limitations of traditional tissue engineering, their technology aims to improve patient outcomes in disease treatment.

Allevi provides 3D bioprinters equipped with patented Cell Optimized Removable Extruders (CORE™) that enable precise printing with various bioinks and cell lines for applications in tissue engineering and disease modeling. The technology addresses the need for versatile and efficient bioprinting solutions, allowing researchers to create complex tissue structures without the need for multiple printheads or extensive calibration.

Criocore provides an automated 3D bioprinting platform that creates human tissue constructs for preclinical drug efficacy and toxicity testing. The scalable, physiologically relevant models integrate with standard assay formats, enabling pharmaceutical and biotech firms to replace animal studies with high‑throughput, human‑relevant data.

Precise Bio develops a 4D bio-fabrication platform that utilizes proprietary single-cell resolution bio-printing technology to create scalable, patient-specific tissues and organs from their own cells. This technology addresses the need for personalized regenerative solutions in various medical fields, including cardiology and orthopedics, by providing a reliable method for producing functional biological structures.

This startup develops organ-ink-based bioprinting technology for regenerative medicine. Their decellularized extracellular matrix serves as a bio-ink to cultivate various cell lines, including stem cell-derived organoids, creating organ-specific microenvironments for tissue regeneration.

REGEMAT3D develops customizable 3D bioprinters that utilize advanced extrusion and temperature control technologies to fabricate living tissues for regenerative medicine. Their systems address the need for precise and adaptable bioprinting solutions in tissue engineering, enabling researchers to create complex biological structures tailored to specific applications.

GenesisTissue develops and manufactures 3D bioprinted tissue implants for regenerative medicine. Their technology aims to create functional tissue replacements for damaged or diseased organs and tissues.

Volumetric Biotechnologies specializes in bioprinting vascularized human tissues using proprietary photoinitiators and polyethylene glycol diacrylate materials. This technology addresses the need for functional tissue constructs in regenerative medicine and drug testing, enhancing the development of complex biological systems.

Healshape develops natural, absorbable bioprosthetic products using 3D bioprinting and tissue engineering to facilitate soft tissue reconstruction. Their first product is a personalized breast bioprosthesis designed for women who have undergone mastectomy due to breast cancer, addressing the need for effective reconstruction solutions.

Ortuvo develops 3D printing research tools and custom bio-inks specifically for tissue engineering applications in the healthcare and biotech sectors. Their technology addresses the need for precise and tailored solutions in regenerative medicine, enhancing the development of biocompatible structures for medical use.

Convo Advanced Manufacturing utilizes acoustic field assembly technology to manipulate cells for the precise construction of functional tissues and organ mimetics. This platform addresses the challenges of traditional biomanufacturing by enabling the creation of complex, three-dimensional structures that closely resemble natural organs, facilitating advancements in regenerative medicine and drug testing.

Linton Lifesciences manufactures off‑the‑shelf hybrid vascular grafts using robotic multi‑material bioprinting that combines synthetic polymer with decellularized human extracellular matrix. The grafts feature a compliant outer layer, a low‑friction endothelial‑friendly lumen, and an embedded broad‑spectrum antimicrobial peptide coating, and are supplied with a sterile procedural kit for rapid intra‑operative deployment. The FDA Class II‑cleared products are sold directly to vascular surgeons and hospital procurement teams.

This startup specializes in 3D bioprinting technology for medical applications, utilizing bioinks to create tissue structures that can enhance regenerative medicine. Additionally, it employs sustainable 3D printing methods to construct housing from renewable waste materials, addressing the need for eco-friendly building solutions.

Prellis utilizes holographic tissue printing technology to create 3D lymph node organoids that replicate human immune responses, enabling the discovery of fully human antibodies with low immunogenicity risk. This approach addresses the challenge of efficiently identifying diverse therapeutic candidates by integrating machine learning with in vitro human biology.

Cymphony Bio develops advanced tools for modeling human health, enabling precise, scalable, and consistent simulations. Their platform helps researchers and developers create and manage complex biological models.

Bio3D Technologies develops scientific 3D printing platforms for research and biomedical applications. Their technology provides affordable and reliable 3D micro-printing and bioprinting solutions for researchers, scientists, and medical professionals.

MimiX Biotherapeutics utilizes Sound Induced Morphogenesis to biofabricate artificial human organs and tissues by manipulating sound profiles to pattern biological materials in a contactless environment. This technology addresses the challenge of creating complex, functional tissues for regenerative medicine, enhancing the scalability and accessibility of biofabrication methods.

Quantis Biotechnology develops human biomaterials for advanced cell culture and tissue engineering. Their proprietary biofabrication process creates scalable, biocompatible proteins that mimic native extracellular matrix, enhancing cell adhesion and tissue model fidelity for researchers and medical device developers.

Systemic Bio develops vascularized organ models using hydrogels and human cells, enabling more accurate preclinical drug testing. Their proprietary 3D Systems technology offers significantly larger build volumes and higher resolution than existing methods, facilitating the creation of customizable organ-on-chip systems for drug discovery.

Dimension Inx develops biomaterials that create regenerative microenvironments to enhance cell functionality and restore organ function. Their technology addresses the limitations of traditional cell therapies by providing a three-dimensional matrix that promotes vascular integration and durable therapeutic responses.

This company develops high-fidelity organoid models and 3D organoid printers that accurately replicate the physiological state of original tissues. Their multi-cell type organoids serve as patient surrogates, providing advanced solutions for drug testing and research.

The startup provides biotechnology products and research services for 3D cell, tissue, and organoid culture, utilizing pharmaceutical-grade materials that maintain the bioactivity of natural extracellular matrices. This enables animal-free drug discovery and development, offering a more ethical approach to pharmaceutical research while ensuring mechanical tunability and reproducibility.

Lattice Medical develops 3D printed bioabsorbable implants for breast reconstruction and soft tissue regeneration, utilizing advanced biomaterials and tissue engineering techniques. Their products, MATTISSE and RODIN, address the need for effective and safe solutions in reconstructive surgery, enhancing patient recovery and outcomes.

CoraMetix develops next-generation aortic heart valves using specialized biopolymers manufactured via advanced 3D printing. These bioinspired valves offer superior performance and durability compared to current animal tissue replacements. The advanced manufacturing process also enables cost-effective production of bespoke medical devices tailored to individual patients.

CapsaLab develops modular AI-driven biofabrication platforms for precision medicine.Their technology integrates artificial intelligence with advanced manufacturing to create patient-specific biological constructs. This enables tailored therapeutic solutions and faster development cycles in personalized healthcare.

Biodimension develops biofabricated human tissues and organoids for drug and cosmetic safety testing, providing a non-animal alternative that yields more relevant human data. Their technology enhances the drug discovery process by offering customized, three-dimensional tissue models that accurately replicate human biological responses.

Triastek utilizes its proprietary Melt Extrusion Deposition (MED®) 3D printing technology to create precise solid dosage forms of pharmaceuticals, enabling tailored drug delivery and improved patient outcomes. The startup addresses challenges in drug formulation and production efficiency, accelerating the development of new medications through continuous manufacturing processes.

This company creates custom 3D-printed surgical devices and anatomical models for complex reconstructive procedures. Their technology allows for the precise replication of bone structures, improving patient outcomes by restoring function and mobility.

GyroGel manufactures patient‑specific bio‑ceramic gyroid scaffolds that combine mineral 3D printing with an FDA‑approved polymer cryogel to mimic cancellous bone. The custom grafts are implanted during a single surgery to regenerate mandibular bone after tumor resection, reducing the need for multiple procedures and lowering reconstruction costs. Revenue is generated by selling these one‑time surgical implants directly to hospitals and surgical centers treating head and neck cancer patients.

PhosPrint P.C. develops a laser bioprinting system that precisely delivers viable cells and bioinks for tissue regeneration and biosensor applications. This technology provides a novel method for treating bladder cancer, offering a safer alternative to existing treatment options.

VoxCell engineers 3D bioprinted, vascularized human tissue models to enhance preclinical drug discovery. These physiologically relevant microphysiological systems mimic in-vivo microenvironments, offering predictive insights superior to traditional animal models. The functional microvascular networks enable realistic drug delivery and distribution studies for improved therapeutic development.

Ronawk develops Bio-Blocks, a 3D tissue-mimetic porous hydrogel substrate that creates bio-mimetic microenvironments for cell and tissue culture, enabling real-time observation and manipulation of cellular functions. This technology addresses the limitations of traditional 2D cell culture methods, which fail to replicate the in vivo environment and often lead to senescence and reduced regenerative capacity in cells.

Biokraft Foods produces cultivated chicken and trout fillets by expanding immortalized avian cells in a defined, antibiotic‑free medium and printing them with a food‑grade bioink using high‑resolution 3D bioprinting. The process creates structured meat analogues with texture and flavor comparable to conventional cuts, offering food manufacturers a scalable, sustainable, and cruelty‑free protein ingredient.

3D Bio-Tissues utilizes bioprinting techniques to create bio-equivalent tissues for clinical and cellular agriculture applications. This technology provides a sustainable alternative to conventional tissue production, meeting the demand for ethical and scalable solutions in the medical and agricultural sectors.

Poietis has developed a patented Next Generation Bioprinting (NGB) platform that utilizes Laser-Assisted Bioprinting and bio-extrusion techniques to create complex 3D tissue models with micron-level precision. This technology enables researchers and clinicians to produce viable, implantable tissues, facilitating advancements in regenerative medicine and accelerating the transition from research to clinical applications.

Readily3D offers a tomographic bioprinter that rapidly solidifies photosensitive inks to create centimeter-scale living tissue constructs in seconds. The light-based process provides sub‑100 µm optical resolution without shear stress, preserving cell viability with low photoinitiator concentrations and light doses. Integrated software imports STL files and controls print parameters, streamlining design iterations and statistical studies for biofabrication research.

Lazarus 3D provides patient-specific 3D-printed surgical models made from soft synthetic polymers that replicate human tissue, allowing surgeons to rehearse procedures with precision. This technology enhances surgical planning and reduces patient risk by enabling practitioners to practice complex techniques on realistic anatomical replicas before actual operations.

The startup develops custom 3D-printed artificial bone implants tailored to the unique anatomy of each patient, co-designed with surgeons to ensure precise fit and functionality. This technology addresses the limitations of standard implants, enhancing surgical outcomes and improving personalized patient care.

Cellink develops advanced 3D bioprinters and bioinks for the precise fabrication of human tissues, enabling researchers to create patient-specific models for personalized medicine and drug discovery. Their technology addresses the need for more physiologically relevant models in biomedical research, enhancing the understanding of human biology and accelerating therapeutic development.

Loominus offers a unified platform for 3D biofabrication workflows, combining Loominus Studio software and BioLoom multi-tool 3D printer to enable researchers to design and produce complex biomaterials with high reproducibility. This integrated solution addresses the challenges of workflow complexity and reproducibility in regenerative medicine, accelerating the development and commercialization of advanced medical therapies.

Brinter develops 3D bioprinted implants for human tissue repair across orthopedic and aesthetic applications. The company utilizes patented 3D BioPrinter technology for scalable, automated mass manufacturing of medical devices. Their implants feature biomimetic architecture and bioactive materials designed to accelerate tissue regeneration and integrate with the patient's body.

TissueLabs provides a platform for 3D bioprinting that includes bioprinters, bioinks, and hydrogels to facilitate the creation of lab-grown tissues and organs. This technology addresses the need for reliable and reproducible models in tissue engineering and regenerative medicine, enhancing research capabilities and accelerating drug discovery.

FluidForm Bio utilizes patented FRESH™ technology to bioprint living human tissue that incorporates cells and vasculature, enabling effective treatments for various diseases. This technology addresses the need for high-quality, functional tissue for applications in tissue restoration, repair, and cell therapy.

FineCell produces micro- and nanocellulose using patented technology to provide sustainable, bio-based materials for personal care products and consumer goods. Their solutions replace fossil-derived ingredients, enabling manufacturers to create differentiated products while significantly reducing carbon footprints.

3D BioFibR produces collagen fibers using patented dry-spinning technology, enabling the commercial-scale manufacturing of materials that mimic the biomechanical and biochemical properties of natural collagen. These fibers are designed for tissue engineering applications, including 3D bioprinting additives and cellular scaffolds, addressing the need for reliable and scalable biomaterials in regenerative medicine.

StemSight develops off-the-shelf cell therapies using induced pluripotent stem (iPS) cells combined with functional biomaterials to regenerate retinal cells. The company targets corneal blindness caused by degenerative eye diseases, aiming to restore vision through effective cellular interventions.

The startup develops three-dimensional-printed bone implants using computer-aided design and a calcium phosphate-fatty acid composite that integrates with the body over time. These implants aim to reduce surgical complications and enhance recovery times for patients with tissue and bone damage, while also lowering procedural costs.

This company produces biocompatible artificial spider silk using bacteria for medical applications. The resulting material offers high strength, elasticity, and biodegradability, enabling new approaches to tissue regeneration and reconstructive surgery.